title: Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).
authors.affiliation: Institut Paoli Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: D
authors.initials: D
authors.lastname: Olive
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: C
authors.initials: C
authors.lastname: Bellanger
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: E
authors.initials: E
authors.lastname: Vilmer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003524:Cyclosporins / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007938:Leukemia / Q000601:surgery; D008727:Methotrexate / Q000627:therapeutic use; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D015375:Receptors, Interleukin-2; D008727:Methotrexate